Literature DB >> 10080429

Association of left ventricular systolic performance and cavity size with angiotensin-converting enzyme genotype in idiopathic dilated cardiomyopathy.

G P Candy1, D Skudicky, U K Mueller, A J Woodiwiss, K Sliwa, F Luker, J Esser, P Sareli, G R Norton.   

Abstract

The insertion-deletion (ID) polymorphism of the angiotensin-converting enzyme (ACE) gene is a marker linked to differences in plasma and cardiac ACE activity as well as to an increased mortality in patients with idiopathic heart failure. We examined the possibility that ACE gene ID variants are associated with differences in left ventricular (LV) systolic performance or internal LV dimensions in a high-risk cohort of patients with idiopathic dilated cardiomyopathy (IDC). The ACE genotype was determined in 171 patients selected with IDC in New York Heart Association functional class II to III heart failure and with a LV ejection fraction of < or = 40%. Left ventricular performance and dimensions were assessed using echocardiography (n = 161) and radionuclide ventriculography (n = 169). The frequency of ACE gene ID alleles was not different in the study versus non-age-matched (n = 171; odds ratio 0.94) and age-matched (n = 106, odds ratio 0.88) control groups. Ejection fraction was found to be worse in patients with the DD genotype (echocardiography, DD = 23.5 +/- 0.70, ID + II = 26.8 +/- 0.8, p = 0.009; ventriculography, DD = 21.7 +/- 0.9, ID + II = 25.3 +/- 0.8, p = 0.003). LV end-systolic and end-diastolic diameters were increased in patients with the DD genotype. Multifactor regression analysis showed the ACE genotype to be an independent predictor of both ejection fraction (echocardiography, p <0.02; ventriculography, p <0.03) and end-diastolic diameter (p <0.02). In conclusion, the results of this study indicate that the DD genotype of the ACE gene is independently associated with both a reduced LV systolic performance and an increased LV cavity size in patients with IDC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10080429     DOI: 10.1016/s0002-9149(98)00981-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  11 in total

1.  Association of angiotensin-converting enzyme I/D polymorphism with heart failure: a meta-analysis.

Authors:  Yuanyuan Bai; Liang Wang; Shengshou Hu; Yingjie Wei
Journal:  Mol Cell Biochem       Date:  2011-10-21       Impact factor: 3.396

2.  Angiotensin-converting enzyme genetic polymorphism.

Authors:  Somsri Wiwanitkit; Viroj Wiwanitkit
Journal:  Arq Bras Cardiol       Date:  2014-06       Impact factor: 2.000

Review 3.  The genomics of cardiovascular disorders: therapeutic implications.

Authors:  P Ferrari; G Bianchi
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

Review 4.  Practical Pharmacogenomic Approaches to Heart Failure Therapeutics.

Authors:  Chayakrit Krittanawong; Amalia Namath; David E Lanfear; W H Wilson Tang
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-10

Review 5.  Genetics of inherited cardiomyopathies in Africa.

Authors:  Gasnat Shaboodien; Timothy F Spracklen; Stephen Kamuli; Polycarp Ndibangwi; Carla Van Niekerk; Ntobeko A B Ntusi
Journal:  Cardiovasc Diagn Ther       Date:  2020-04

Review 6.  The role and regulation of cardiac angiotensin-converting enzyme for noninvasive molecular imaging in heart failure.

Authors:  Omer Aras; Steven A Messina; Jamshid Shirani; William C Eckelman; Vasken Dilsizian
Journal:  Curr Cardiol Rep       Date:  2007-04       Impact factor: 2.931

7.  Drug Treatment of Heart Failure in Children: Focus on Recent Recommendations from the ISHLT Guidelines for the Management of Pediatric Heart Failure.

Authors:  Alexander D Hussey; Robert G Weintraub
Journal:  Paediatr Drugs       Date:  2016-04       Impact factor: 3.022

Review 8.  Rescue of familial cardiomyopathies by modifications at the level of sarcomere and Ca2+ fluxes.

Authors:  Marco L Alves; Robert D Gaffin; Beata M Wolska
Journal:  J Mol Cell Cardiol       Date:  2010-01-15       Impact factor: 5.000

9.  Beta1- and alpha2c-adrenoreceptor variants as predictors of clinical aspects of dilated cardiomyopathy in people of African ancestry.

Authors:  A J Woodiwiss; D Badenhorst; K Sliwa; R Brooksbank; R Essop; P Sareli; G R Norton
Journal:  Cardiovasc J Afr       Date:  2008 Jul-Aug       Impact factor: 1.167

10.  Angiotensin-converting enzyme genetic polymorphism: its impact on cardiac remodeling.

Authors:  Felipe Neves de Albuquerque; Andréa Araujo Brandão; Dayse Aparecida da Silva; Ricardo Mourilhe-Rocha; Gustavo Salgado Duque; Alyne Freitas Pereira Gondar; Luiza Maceira de Almeida Neves; Marcelo Imbroinise Bittencourt; Roberto Pozzan; Denilson Campos de Albuquerque
Journal:  Arq Bras Cardiol       Date:  2013-11-26       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.